scopolamine patch — Competitive Intelligence Brief

scopolamine patch (scopolamine patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent. Area: Gastroenterology / Neurology.

marketed Anticholinergic agent Muscarinic acetylcholine receptors (M1, M3, M5) Gastroenterology / Neurology Small molecule

Target snapshot

scopolamine patch (scopolamine patch) — Rutgers, The State University of New Jersey. Scopolamine blocks muscarinic acetylcholine receptors in the central nervous system to prevent nausea and vomiting.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
scopolamine patch TARGET	scopolamine patch	Rutgers, The State University of New Jersey	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors (M1, M3, M5)
Atropine 0.01%	Atropine 0.01%	University Hospital, Strasbourg, France	marketed	Anticholinergic agent / Muscarinic antagonist	Muscarinic acetylcholine receptors (M1-M5)
Neostigmine + Glycopyrrolate	Neostigmine + Glycopyrrolate	Merck Sharp & Dohme LLC	marketed	Acetylcholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate)
Intravenous scopolamine hydrobromide	Intravenous scopolamine hydrobromide	University of Iowa	marketed	Anticholinergic agent	Muscarinic acetylcholine receptors
neostigmine/glycopyrolate	neostigmine/glycopyrolate	Henry Ford Health System	marketed	Cholinesterase inhibitor with anticholinergic agent	Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrolate)
Bencycloquidium Bromide Nasal Spray	Bencycloquidium Bromide Nasal Spray	Yingu Pharmaceutical Co., Ltd	marketed	Anticholinergic agent	Muscarinic acetylcholine receptor (M3)
Atropine Sulfate 0.04% Eye Drop	Atropine Sulfate 0.04% Eye Drop	Shanghai Eye Disease Prevention and Treatment Center	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1, M3, M5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent class)

1. Repurposed Therapeutics, Inc. · 2 drugs in this class
2. University of Iowa · 2 drugs in this class
3. Alza Corporation, DE, USA · 2 drugs in this class
4. Janssen-Cilag Ltd.,Thailand · 1 drug in this class
5. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
6. Rutgers, The State University of New Jersey · 1 drug in this class
7. Stony Brook University · 1 drug in this class
8. Toronto Rehabilitation Institute · 1 drug in this class
9. US Department of Veterans Affairs · 1 drug in this class
10. University of California, Davis · 1 drug in this class